Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asentar with Gemcitabine ± Erlotinib in Advanced Pancreatic Cancer
NCT00536770Phase 2Suspended
- Sponsor
- Novacea
- Start
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Asentar in pancreatic adenocarcinoma (PDAC), sponsored by Novacea. Started Sep 2007; status: suspended.
02
Drugs
Asentar
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00536770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00536770.